NAALAD2

Across TCGA pan-cancer cohorts, NAALAD2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NAALAD2 data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher NAALAD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAALAD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, HNSC, and UCEC are the cancer types where NAALAD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.137	0.639	<.001	36	view →
HNSC	OS	Median	All	0.289	0.688	.009	13	view →
UCEC	DFS	Median	All	0.947	0.620	.009	12	view →
LIHC	OS	Median	All	0.098	0.774	.001	6	view →
SKCM	DFS	Median	All	0.617	0.746	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NAALAD2–SCLC (DFS)

Open the SCLC breakdown →